TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of “Buy” by Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.08.

TLSI has been the topic of several recent research reports. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm started coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective for the company. Canaccord Genuity Group decreased their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock.

TriSalus Life Sciences Trading Down 1.5 %

Shares of NASDAQ TLSI opened at $3.91 on Friday. The firm has a market cap of $119.23 million, a P/E ratio of -1.57 and a beta of 0.56. The business’s 50 day moving average is $4.19 and its 200-day moving average is $5.05. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42.

Institutional Trading of TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Walleye Capital LLC bought a new position in TriSalus Life Sciences in the third quarter valued at approximately $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences during the third quarter worth $92,000. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $184,000. Finally, Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $240,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.